Abivax Société Anonyme has raised $920 million to support the development of obefazimod, a novel oral therapy for ulcerative colitis and Crohn’s disease. The funding extends the company's cash runway into the fourth quarter of 2029 and strengthens its position for possible mergers or acquisitions. While the stock is currently fairly valued in the $90 range, future upside depends on receiving a favorable label for ulcerative colitis and positive Phase 2b data for Crohn’s disease expected in 2027. The company carries risks including clarity on regulatory labeling, competition, and reliance on a single drug asset. The analyst maintains a Hold rating due to the drug’s blockbuster potential balanced against these uncertainties.
Abivax's recent $920 million funding round for its ulcerative colitis and Crohn’s disease drug development provides a backdrop for health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Sep 24, 2026 00:03 WIB: Of 100 priced US health-sector stocks tradable on Pluang, 14 rose and 85 fell. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 25.00 with a -5.34% change and a typical hold time of 77 days, Ascendis Pharma A/S (ASND) at USD 225.05 down 5.27% with a 55-day hold, and Ginkgo Bioworks Holdings Inc (DNA) at USD 8.90 down 5.02%, with a typical hold time of 10 days and Pluang order activity showing 37% sell and 63% buy.
Jefferies reaffirmed its Buy rating on Life Time Group Holdings (LTH), citing a positive earnings outlook supported by a Zacks Rank of #2. The stock trades around $38.85 with a market cap near $8.68 billion. Despite this optimism, Executive Vice Pres...
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...
SpaceX stock fell 4% to $148.13 due to concerns over a large share unlock on September 24 and a $52 million stock sale by COO Gwynne Shotwell. Investors are also cautious about the company's high valuation following its June IPO, despite growth prosp...
IM Cannabis Corp. announced it has regained compliance with Nasdaq's minimum bid price rule after its share price stayed at or above $1.00 for 18 consecutive business days. This compliance removes the risk of delisting from Nasdaq. The company operat...
